Home

WESEEYOUâ„¢

Intercept’s commitment to research is a commitment to you

The advances we are making in the development of novel treatments for liver diseases such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH) have the potential to change the lives of patients and physicians who currently have few, if any, therapeutic options.

LEARN ABOUT PBC AND NASH >

News

Monday, May 4, 2015

Intercept to Report First Quarter 2015 Financial Results on May 11 and Present at Upcoming Conferences
See the press release >